This article is more than 5 years old. Information may no longer be current.

CMS issues preliminary decision on J code for Avedro's Photrexa

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CMS has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System J code for Photrexa drug formulations, according to a press release from Avedro.

Photrexa formulations are the only drugs approved by the FDA for use with the KXL System in corneal cross-linking, and if finalized, a J code will simplify billing for the procedure, the release said.

“A product specific J code will streamline the claims submission process for physician practices and better serve ectatic patients in need of treatment,” OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, said in the release.

The decision is expected to be finalized in November, with new and revised codes becoming effective Jan. 1, 2019, the release said.